Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-101,606 in Treatment Refractory Major Depressive Disorder
NCT00163059Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing CP-101,606 + Paroxetine with Placebo + Paroxetine (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 5. Started May 2004; status: completed.
02
Drugs
traxoprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00163059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163059.